Wednesday, July 26, 2017

Enter Title

Minimize
*|MC:SUBJECT|*
Veletri now available in NZ
View email in browser.

Veletri® (epoprostenol intravenous) – for the treatment of pulmonary arterial hypertension (PAH) is now available on the New Zealand Pharmaceutical Schedule 

 

21 September, 2015: Actelion Pharmaceuticals Australia Pty Ltd announces the listing of Veletri® (epoprostenol IV) from 1 September 2015 in Part II of Section H (the Hospital Medicines List or HML) of the Pharmaceutical Schedule, for use as a bridge to transplant for patients with PAH who are on the active waiting list for lung transplantation1.
 

PAH is a rare but potentially fatal disease causing high blood pressure in the arteries between the heart and lungs of patients. The chronic disease leads to increasing limitations on physical activity and life expectancy. Worldwide prevalence estimates vary from 15 to 26 cases per million up to 50 to 70 cases per million. 
 

Veletri® was MedSafe (New Zealand Medicines and Medical Devices Safety Authority) approved in August 2014, for the long-term treatment, via continuous intravenous infusion, in WHO functional class III or class IV patients with: idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases1
 

Veletri® is available in two strengths; 0.5 mg and 1.5 mg vials, and can be reconstituted with sodium chloride 0.9% solution for injection or sterile water for injection. 
 

The formulation of Veletri® has been developed to prolong stability once reconstituted. Veletri® offers two preparation and storage options for patients: 
 

1 – Prepare and use immediately1: Fully diluted Veletri® can be administered for up to 48 hours at room temperature (25oC) at concentrations ≥ 3000 ng/mL. 

2 – Prepare and store for up to 8 days in refrigerator before use1: Fully diluted Veletri® can be stored in the refrigerator (i.e. 2oC to 8oC) for up to 8 days and then administered at room temperature (25oC) for up to 24 hours at concentrations between 3000 ng/mL and 15000 ng/mL and up to 48 hours at concentrations ≥ 15000 ng/mL. 
 

VELETRI® is a registered trademark of Actelion Pharmaceuticals Ltd. and is sponsored by Healthcare Logistics, Auckland. 
 

Should you have any questions or require additional information, please contact Actelion Australia Medical Information on +61 2 9486 4600.

Full NZ Veletri Press Release
Share
Tweet
Forward
Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

Our mailing address is:
*|HTML:LIST_ADDRESS_HTML|* *|END:IF|*

unsubscribe from this list    update subscription preferences 

*|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*
Copyright 2011 by PHSANZ